The HSE has approved seven new treatments for osteoporosis, antimicrobial-resistant infections, and cancer, among other conditions. The drugs will be funded from a €20 million allocation for new medicines this year. HSE’s chief clinical officer, Dr. Colm Henry, highlighted the significance of these new medications in meeting previously unmet needs and targeting specific at-risk groups. The new treatments include a first-in-class medication for severe osteoporosis, a new drug for antimicrobial-resistant infections, and medications for non-small cell lung cancer and transplant patients. The HSE also approved reimbursement for a gene therapy for the rare condition metachromatic leukodystrophy, which was previously priced at €2.8 million for a one-off dose.
Source link
HSE approves seven new treatments for range of conditions
